Key facts
- This page summarizes Patrick Lin's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 01 Feb 2024, 18:32.
Patrick Lin - 31 Jan 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)
- Reporting relationship
- Chief Business - Strategy Off
- Issuer ticker
- PCSA
- Reported as of
- 31 Jan 2024
- Net transaction value
- +$9,525
- SEC form
- 4
- Accepted by SEC
- 01 Feb 2024, 18:32:03 UTC
- Prior SEC filing
- 12 Apr 2024
- Next SEC filing
- 02 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lin filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 01 Feb 2024.
Change
- Previous filing in this sequence was filed on 12 Apr 2024.
- Current net transaction value: +$9,525.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCSA
transaction
Common Stock
Purchase
- Transaction value
- $5,925
- Shares
- +2,500
- Change %
- +11%
- Price
- $2.37
- Shares after
- 25,978
- Date
- 31 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
PCSA
transaction
Common Stock
Purchase
- Transaction value
- $3,600
- Shares
- +1,500
- Change %
- +5.8%
- Price
- $2.40
- Shares after
- 27,478
- Date
- 01 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.